- Home
- PHLT vs LXEO Comparison
PHLT vs LXEO Comparison
Compare PHLT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- LXEO
- Stock Information
- Founded
- PHLT 1976
- LXEO 2017
- Country
- PHLT United States
- LXEO United States
- Employees
- PHLT N/A
- LXEO N/A
- Industry
- PHLT Other Consumer Services
- LXEO
- Sector
- PHLT Consumer Discretionary
- LXEO
- Exchange
- PHLT Nasdaq
- LXEO Nasdaq
- Market Cap
- PHLT 215.3M
- LXEO 252.4M
- IPO Year
- PHLT N/A
- LXEO 2023
- Fundamental
- Price
- PHLT $2.43
- LXEO $4.88
- Analyst Decision
- PHLT
- LXEO Strong Buy
- Analyst Count
- PHLT 0
- LXEO 5
- Target Price
- PHLT N/A
- LXEO $23.80
- AVG Volume (30 Days)
- PHLT 168.5K
- LXEO 210.0K
- Earning Date
- PHLT 03-11-2025
- LXEO 01-28-2025
- Dividend Yield
- PHLT N/A
- LXEO N/A
- EPS Growth
- PHLT N/A
- LXEO N/A
- EPS
- PHLT N/A
- LXEO N/A
- Revenue
- PHLT $120,782,000.00
- LXEO N/A
- Revenue This Year
- PHLT $9.72
- LXEO N/A
- Revenue Next Year
- PHLT $9.90
- LXEO N/A
- P/E Ratio
- PHLT N/A
- LXEO N/A
- Revenue Growth
- PHLT 9.39
- LXEO N/A
- 52 Week Low
- PHLT $2.29
- LXEO $4.78
- 52 Week High
- PHLT $4.35
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- PHLT N/A
- LXEO 29.67
- Support Level
- PHLT N/A
- LXEO $4.78
- Resistance Level
- PHLT N/A
- LXEO $7.66
- Average True Range (ATR)
- PHLT 0.00
- LXEO 0.56
- MACD
- PHLT 0.00
- LXEO -0.17
- Stochastic Oscillator
- PHLT 0.00
- LXEO 3.47
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc delivers payment integrity solutions for its healthcare payer clients.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.